Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial

PROTECT Study Group

Research output: Contribution to journalArticlepeer-review

47 Citations (Scopus)
Original languageEnglish
Pages (from-to)1271-1281
Number of pages11
JournalThe Lancet Infectious Diseases
Volume21
Issue number9
DOIs
Publication statusPublished - Sept 2021
Externally publishedYes

ASJC Scopus Subject Areas

  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial'. Together they form a unique fingerprint.

Cite this